MARKET

IRWD

IRWD

Ironwood Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

10.35
+0.13
+1.22%
After Hours: 10.35 0 0.00% 16:00 07/15 EDT
OPEN
10.36
PREV CLOSE
10.22
HIGH
10.44
LOW
10.24
VOLUME
1.68M
TURNOVER
--
52 WEEK HIGH
14.10
52 WEEK LOW
7.91
MARKET CAP
1.65B
P/E (TTM)
19.27
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 7 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average IRWD stock price target is 12.00 with a high estimate of 14.00 and a low estimate of 10.00.

EPS

IRWD News

More
Morgan Stanley Maintains Equal-Weight on Ironwood Pharmaceuticals, Lowers Price Target to $10
Morgan Stanley maintains Ironwood Pharmaceuticals (NASDAQ:IRWD) with a Equal-Weight and lowers the price target from $11 to $10.
Benzinga · 8h ago
Did Hedge Funds Make The Right Call On Ironwood Pharmaceuticals, Inc. (IRWD) ?
At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (see why hell is coming). In these volatile markets we scrutinize hedge fund filings to get a reading on which
Insider Monkey · 2d ago
Hedge Funds Still Bullish On Ironwood Pharmaceuticals, Inc. (IRWD)
Insider Monkey · 06/08 07:51
Why Is Ironwood (IRWD) Down 3.6% Since Last Earnings Report?
Zacks · 06/05 16:31
Biotech Stock Roundup: GILD's Coronavirus Drug Update, NTLA-REGN Deal & More
Zacks · 06/03 14:56
Ironwood Pharmaceuticals (IRWD) Looks Good: Stock Adds 7.6% in Session
Zacks · 06/03 14:04
Edited Transcript of IRWD earnings conference call or presentation 6-May-20 8:30pm GMT
Thomson Reuters StreetEvents · 06/03 13:32
Credit Suisse Maintains Neutral on Ironwood Pharmaceuticals, Lowers Price Target to $11
Credit Suisse maintains Ironwood Pharmaceuticals (NASDAQ:IRWD) with a Neutral and lowers the price target from $12 to $11.
Benzinga · 06/01 12:54

Industry

Biotechnology & Medical Research
+1.38%
Pharmaceuticals & Medical Research
+1.63%

Hot Stocks

Symbol
Price
%Change

About IRWD

Ironwood Pharmaceuticals, Inc. is a biotechnology company. The Company is advancing product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC), hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease (uncontrolled GERD), and vascular and fibrotic diseases. It operates in human therapeutics business segment. Its product, linaclotide, is available to adult men and women suffering from IBS C or CIC in the United States under the trademarked name LINZESS, and is available to adult men and women suffering from IBS C in certain European countries under the trademarked name CONSTELLA. It is also advancing IW-3718, a gastric retentive formulation of a bile acid sequestrant with the potential to provide symptomatic relief in patients with uncontrolled GERD. Its vascular/fibrotic programs include IW-1973 and IW-1701, which targets soluble guanylate cyclase (sGC).
More

Webull offers kinds of Ironwood Pharmaceuticals, Inc. stock information, including NASDAQ:IRWD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IRWD stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading IRWD stock methods without spending real money on the virtual paper trading platform.